



## EDITORIAL COMMENT

## The new Clinical Kidney Journal, 4 years later

Alberto Ortiz<sup>1</sup> and Caroline Vinck<sup>2</sup>

<sup>1</sup>Editor-in-Chief, Clinical Kidney Journal, IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de Madrid; Fundacion Renal Iñigo Alvarez de Toledo-IRSIN and REDINREN, Madrid, Spain and

<sup>2</sup>ERA-EDTA Editorial Office Coordinator, Lede, Belgium

Correspondence and offprint requests to: Alberto Ortiz; E-mail: aortiz@fjd.es

### ABSTRACT

The February 2015 issue of *ckj* started a new era with renewed efforts to be useful to the training and practicing nephrologists and a new focus on Clinical and Translational Nephrology. Four years later, it has become a truly global journal with contributors and readers from all over the world. The increase in quality of the published material has resulted in a nearly exponential growth of citations. Since 2016, *ckj* is listed in the new Emerging Sources Citation Index (ESCI) database from Clarivate Analytics and from January 2019 it will be listed in the full Science Citation Index. *ckj* will therefore receive its first official impact factor based upon 2018 citation to 2016 and 2017 articles. While no official impact factor was awarded for 2017, the estimated impact factors calculated from data available in Clarivate's Web of Science database rose to 2.987 in 2017, which would correspond to an estimated journal impact factor percentile of 72.4% in the Urology and Nephrology field.

**Keywords:** acute kidney injury, chronic kidney disease, epidemiology, onconeurology

*NDT Plus* was launched in 2008. The Editor-in-Chief, Norbert Lameire, aimed at providing an educational and training resource for practicing nephrologists [1]. In 2012, *NDT Plus* evolved into the *Clinical Kidney Journal (ckj)* and flourished as an educational tool under the editorship of Alain Meyrier [2, 3]. In 2015, Alberto Ortiz was elected Editor-in-Chief for a first term that just ended. A sub-heading was added to *ckj* emphasizing the new focus: Clinical and Translational Nephrology [4]. The vision was further expanded in a series of articles on Translational Nephrology [5, 6]. The journal became open access, online-only, and fully searchable and accessible through PubMed. Submission and publishing fees have been waived ever since. The types of manuscripts were streamlined to editorial comments, *ckj* reviews, original articles and exceptional case reports.

Over the past 4 years, the number of published items decreased when compared with the younger *ckj* (Figure 1A). This was a consequence of a higher quality threshold for publication. Thus, the number of submissions was 449 in 2015 and is

expected to hover around 480 in 2018. However, the acceptance rate decreased from 40% in 2013 to 36% in 2015 and 26% in 2018. The types of manuscripts published shifted to an increase of high-quality *ckj* reviews and original manuscripts. These changes were well received by the nephrological community and the number of citations per year exponentially increased (Figure 1B). In 2016, *ckj* was accepted for indexing in the new Emerging Sources Citation Index (ESCI) database from Clarivate Analytics (previously Thomson Reuters). From January 2019 it will be listed in the full Science Citation Index. *ckj* will therefore receive its first official impact factor based upon 2018 citation to 2016 and 2017 articles. While no official impact factor was awarded for 2017, the estimated impact factor calculated from data available in Clarivate's Web of Science database rose to 2.987 in 2017 (Figure 2A). In this regard, it is estimated that *ckj* is approaching the first quartile (Q1, 25% top journals as assessed by impact factor) in the Urology and Nephrology field (Figure 2B). In the 2017 impact factor database, released in June

Received: 31.12.2018; Editorial decision: 31.12.2018

© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)




FIGURE 1: *ckj* over the years. (A) Number of published items. (B) Number of citations per year according to Web of Science, accessed 18 December 2018.

2018, there were 10 Urology and 9 Nephrology journals in Q1. Of the latter, only five published original manuscripts.

*ckj* has become a global reference for practicing nephrologists. The main geographical origin of submissions is the USA (22–25% across 2015–18). On the other side of the coin, the top five user countries were, in this order, USA, Great Britain, India, Canada and Australia. However, there were users from a total of 210 countries in 2018, making it a truly global journal (Figure 3).

The most cited manuscripts in this new era are listed in Tables 1–3. Over the past 4 years, the most cited items were ERA-EDTA Registry reports and systematic reviews (Table 1) [7–18]. As expected, older items have gathered more citations. Thus, we provide one table focusing on 2017 (Table 2) and one for 2018 (Table 3) [19–45]. Among the most cited topics, we find systematic reviews and meta-analysis on exercise, vitamins K and D, and assessment of renal function and injury, including the use of a urine peptidomics-based marker of kidney injury recently refined to beat glomerular filtration rate and urinary albumin:creatinine ratio for prediction of chronic kidney disease (CKD) progression when the estimated glomerular filtration rate is still not diagnostic of CKD [46]. Other topics that drew the attention of authors were onconephrology, the interrelationship of the gut microbiota and kidney disease, low-protein diets, residual renal function, eculizumab, sustainability of renal replacement therapy, socioeconomic and psychosocial factors and gender impact on CKD, CKD hotspots, management of hyperphosphataemia, hyperkalaemia, hyperuricaemia and acute kidney injury (AKI). Many topics were shared with the 100 most cited papers in nephrology, presented in this issue of *ckj*, suggesting overall clinical interest for the nephrological community. Shared topics include renal function assessment, pharmacology, dialysis/transplantation, AKI and CKD [47].

In contrast, the top downloaded articles were very practical in approach and included the 2017 update on pain management in patients with CKD [48] and a manuscript on palliative care for patients with end-stage renal disease [49], both published in 2017. In 2018, the top downloaded articles dealt with high-dose vitamin




FIGURE 2: *ckj* and estimated impact factor. (A) Estimated impact factors calculated from data available in Clarivate's Web of Science database. They are not official impact factors. (B) Estimated journal impact factor (JIF) percentile in the Urology and Nephrology field.




FIGURE 3: Country of origin of *ckj* online users in 2018. Numbers represent percentage of total individual users.

K for calciphylaxis [50], therapy of childhood C3 glomerulopathy [51] and hyponatraemia in kidney transplant patients [52].

A different vision of the impact of *ckj* is provided by the Altmetrics score. In 2018, the three top manuscripts dealt with the 'ExTra CKD' trial of supervised exercise in CKD [53], living kidney donor use of marijuana [54] and the EMPA-KIDNEY study of sodium/glucose cotransporter 2 (SGLT2) inhibitors in CKD [55].

As part of our focus on education, *ckj* has started a collaboration with GlomCon and the ERA-EDTA Young Nephrologists' Platform in 2018. Up to now, two *ckj* manuscripts have been discussed in the Journal Club webinar with active participation of the Editor-in-Chief and in some cases of the authors [56, 57]. For 2019, the manuscript 'Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network' by Sprangers et al. [58] is scheduled to be discussed on 7 May 2019.

Table 1. Overall most cited items published in 2015–18

Rank	Title	References
1	Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry Annual Report	Pippias et al. [7]
2	Effects of exercise in the whole spectrum of CKD: a systematic review	Barcellos et al. [8]
3	Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus	Kramer et al. [9]
4	The intestine and the kidneys: a bad marriage can be hazardous	Vanholder et al. [10]
5	Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol?	Delanaye et al. [11]
5	Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma	Murakami et al. [12]
5	Strategies for preserving residual renal function in peritoneal dialysis patients	Nongnuch et al. [13]
5	Low-protein diets in CKD: how can we achieve them? A narrative, pragmatic review	Piccoli et al. [14]
6	Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling	Bhatnagar et al. [15]
6	The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials	Caluwé et al. [16]
6	Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis	Mann et al. [17]
6	Chronic kidney disease hotspots in developing countries in South Asia	Abraham et al. [18]

Note: As of 18 December 2018, according to Web of Science.

Table 2. Overall most cited items published in 2017

Rank	Title	References
1	The European Renal Association – European Dialysis and Transplant Association Registry Annual Report 2014: a summary	Pippias et al. [19]
2	Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease	Pontillo and Mischak [20]
2	Age-dependent reference intervals for estimated and measured glomerular filtration rate	Pottel et al. [21]
3	Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome	Macia et al. [22]
3	Cognitive function and advanced kidney disease: longitudinal trends and impact on decision-making	Iyasere et al. [23]
3	Acute kidney injury in patients with severe sepsis or septic shock: a comparison between the ‘Risk, Injury, Failure, Loss of kidney function, End-stage kidney disease’ (RIFLE), Acute Kidney Injury Network (AKIN) and Kidney Disease: Improving Global Outcomes (KDIGO) classifications	Pereira et al. [24]
4	Pregnancy outcomes in women on hemodialysis: a national survey	Sachdeva et al. [25]
4	Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea	Brocklebank and Kavanagh [26]
4	Warfarin-related nephropathy induced by three different vitamin K antagonists: analysis of 13 biopsy-proven cases	Golbin et al. [27]
5	Lesinurad: what the nephrologist should know	Sanchez-Niño et al. [28]
5	Impact of poverty and race on pre-end-stage renal disease care among dialysis patients in the United States	Nee et al. [29]
5	The role of psychological factors in fatigue among end-stage kidney disease patients: a critical review	Picariello et al. [30]

Note: As of 18 December 2018, according to Web of Science.

Hopefully, we will relay to the next Editor-in-Chief, to be elected in 2021, an internationally renowned journal that continues to be a required and useful read for nephrologists in training and practicing nephrologists.

## FUNDING

Alberto Ortiz was funded by Red Nacional de Investigación en Enfermedades renales (RETIC REDINREN) RD16/0009, Instituto de Salud Carlos III (ISCIII); Government of Spain.

## CONFLICT OF INTEREST STATEMENT

None declared.

## REFERENCES

- Lameire N, Floege J, Wheeler DC Note from the Editorial Office. *NDT Plus* 2008; 1: 1
- Meyrier A, Lameire N. NDT plus introduces the *Clinical Kidney Journal*. *NDT Plus* 2011; 4: 367
- Meyrier A. Report from the Editorial Office. *Clin Kidney J* 2012; 5: 1–3
- Ortiz A. Welcome to the new *ckj*: an open-access resource integrating clinical, translational and educational research into clinical practice. *Clin Kidney J* 2015; 8: 1–2
- Ortiz A. Translational nephrology: what translational research is and a bird’s-eye view on translational research in nephrology. *Clin Kidney J* 2015; 8: 14–22

Table 3. Most cited items published in *ckj* in 2018

Rank	Title	References
1	The European Renal Association – European Dialysis and Transplant Association (ERA–EDTA) Registry Annual Report 2015: a summary	Kramer et al. [31]
2	Patterns of progression of chronic kidney disease at later stages	Caravaca-Fontán et al. [32]
2	Pretreatment of enteral nutrition with sodium polystyrene sulfonate: effective, but beware the high prevalence of electrolyte derangements in clinical practice	Le Palma et al. [33]
2	Achievement of Kidney Disease: Improving Global Outcomes mineral and bone targets between 2010 and 2014 in incident dialysis patients in France: the Photo-Grappe3 study	Fouque et al. [34]
2	Women and kidney disease: reflections on World Kidney Day 2018: Kidney Health and Women's Health: a case for optimizing outcomes for present and future generations	Piccoli et al. [35]
3	Cost of hemodialysis in a public sector tertiary hospital of India	Kaur et al. [36]
3	Extracorporeal shock wave lithotripsy versus flexible ureterorenoscopy in the treatment of untreated renal calculi	Fankhauser et al. [37]
3	Do kidney transplantations save money? A study using a before–after design and multiple register-based data from Sweden	Jarl et al. [38]
3	Sevelamer reduces endothelial inflammatory response to advanced glycation end products	Gregório et al. [39]
3	Renal recovery after severe acute kidney injury in critically ill myeloma patients: a retrospective study	Joseph et al. [40]
3	Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan	Müller et al. [41]
3	International Society of Nephrology's 0by25 initiative (zero preventable deaths from acute kidney injury by 2025): focus on diagnosis of acute kidney injury in low-income countries	Raimann et al. [42]
3	Lung ultrasonography in end-stage renal disease: moving from evidence to practice—a narrative review	Ross et al. [43]
3	Cardiovascular effects of metabolic syndrome after transplantation: convergence of obesity and transplant-related factors.	Sgambat et al. [44]
3	MicroRNAs: a new avenue to understand, investigate and treat immunoglobulin A nephropathy?	Selvaskandan et al. [45]

Note: As of 18 December 2018, according to Web of Science.

- Brück K, Stel VS, Fraser S et al. Translational research in nephrology: chronic kidney disease prevention and public health. *Clin Kidney J* 2015; 8: 647–655
- Pippias M, Stel VS, Abad Diez JM et al. Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry Annual Report. *Clin Kidney J* 2015; 8: 248–261
- Barcellos FC, Santos IS, Umpierre D et al. Effects of exercise in the whole spectrum of chronic kidney disease: a systematic review. *Clin Kidney J* 2015; 8: 753–765
- Kramer A, Pippias M, Stel VS et al. Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus. *Clin Kidney J* 2016; 9: 457–469
- Vanholder R, Glorieux G. The intestine and the kidneys: a bad marriage can be hazardous. *Clin Kidney J* 2015; 8: 168–179
- Delanaye P, Ebert N, Melsom T et al. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol? *Clin Kidney J* 2016; 9: 682–699
- Murakami N, Borges TJ, Yamashita M et al. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. *Clin Kidney J* 2016; 9: 411–417
- Nongnuch A, Assanatham M, Panorchan K et al. Strategies for preserving residual renal function in peritoneal dialysis patients. *Clin Kidney J* 2015; 8: 202–211
- Piccoli GB, Vigotti FN, Leone F et al. Low-protein diets in CKD: how can we achieve them? A narrative, pragmatic review. *Clin Kidney J* 2015; 8: 61–70
- Bhatnagar V, Richard EL, Wu W et al. Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling. *Clin Kidney J* 2016; 9: 444–453
- Caluwé R, Pyfferoen L, De Boeck K et al. The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. *Clin Kidney J* 2016; 9: 273–279
- Mann MC, Hobbs AJ, Hemmelgarn BR et al. Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis. *Clin Kidney J* 2015; 8: 41–48
- Abraham G, Varughese S, Thandavan T et al. Chronic kidney disease hotspots in developing countries in South Asia. *Clin Kidney J* 2016; 9: 135–141
- Pippias M, Kramer A, Noordzij M et al. The European Renal Association – European Dialysis and Transplant Association Registry Annual Report 2014: a summary. *Clin Kidney J* 2017; 10: 154–169
- Pontillo C, Mischak H. Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease. *Clin Kidney J* 2017; 10: 192–201
- Pottel H, Delanaye P, Weekers L et al. Age-dependent reference intervals for estimated and measured glomerular filtration rate. *Clin Kidney J* 2017; 10: 545–551
- Macia M, de Alvaro Moreno F, Dutt T et al. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. *Clin Kidney J* 2017; 10: 310–319
- Iyasere O, Okai D, Brown E. Cognitive function and advanced kidney disease: longitudinal trends and impact on decision-making. *Clin Kidney J* 2017; 10: 89–94
- Pereira M, Rodrigues N, Godinho I et al. Acute kidney injury in patients with severe sepsis or septic shock: a comparison between the 'Risk, Injury, Failure, Loss of kidney function, End-

- stage kidney disease' (RIFLE), Acute Kidney Injury Network (AKIN) and Kidney Disease: Improving Global Outcomes (KDIGO) classifications. *Clin Kidney J* 2017; 10: 332–340
25. Sachdeva M, Barta V, Thakkar J et al. Pregnancy outcomes in women on hemodialysis: a national survey. *Clin Kidney J* 2017; 10: 276–281
  26. Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. *Clin Kidney J* 2017; 10: 600–624
  27. Golbin L, Vigneau C, Touchard G et al. Warfarin-related nephropathy induced by three different vitamin K antagonists: analysis of 13 biopsy-proven cases. *Clin Kidney J* 2017; 10: 381–388
  28. Sanchez-Niño MD, Zheng-Lin B, Valiño-Rivas L et al. Lesinurad: what the nephrologist should know. *Clin Kidney J* 2017; 10: 679–687
  29. Nee R, Yuan CM, Hurst FP et al. Impact of poverty and race on pre-end-stage renal disease care among dialysis patients in the United States. *Clin Kidney J* 2017; 10: 55–61
  30. Picariello F, Moss-Morris R, Macdougall IC et al. The role of psychological factors in fatigue among end-stage kidney disease patients: a critical review. *Clin Kidney J* 2017; 10: 79–88
  31. Kramer A, Pippias M, Noordzij M et al. The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary. *Clin Kidney J* 2018; 11: 108–122
  32. Caravaca-Fontán F, Azevedo L, Luna E et al. Patterns of progression of chronic kidney disease at later stages. *Clin Kidney J* 2018; 11: 246–253
  33. Le Palma K, Pavlick ER, Copelovitch L. Pretreatment of enteral nutrition with sodium polystyrene sulfonate: effective, but beware the high prevalence of electrolyte derangements in clinical practice. *Clin Kidney J* 2018; 11: 166–171
  34. Fouque D, Roth H, Darné B et al. Achievement of Kidney Disease: Improving Global Outcomes mineral and bone targets between 2010 and 2014 in incident dialysis patients in France: the Photo-Grappe3 study. *Clin Kidney J* 2018; 11: 73–79
  35. Piccoli GB, Alrukhaimi M, Liu Z-H et al. Women and kidney disease: reflections on World Kidney Day 2018: Kidney Health and Women's Health: a case for optimizing outcomes for present and future generations. *Nephrol Dial Transplant* 2018; 33: 189–193
  36. Kaur G, Prinja S, Ramachandran R et al. Cost of hemodialysis in a public sector tertiary hospital of India. *Clin Kidney J* 2018; 11: 726–733
  37. Fankhauser CD, Hermanns T, Lieger L et al. Extracorporeal shock wave lithotripsy versus flexible ureterorenoscopy in the treatment of untreated renal calculi. *Clin Kidney J* 2018; 11: 364–369
  38. Jarl J, Desatnik P, Peetz Hansson U et al. Do kidney transplantations save money? A study using a before-after design and multiple register-based data from Sweden. *Clin Kidney J* 2018; 11: 283–288
  39. Gregório PC, Favretto G, Sasaki GL et al. Sevelamer reduces endothelial inflammatory response to advanced glycation end products. *Clin Kidney J* 2018; 11: 89–98
  40. Joseph A, Harel S, Venot M et al. Renal recovery after severe acute kidney injury in critically ill myeloma patients: a retrospective study. *Clin Kidney J* 2018; 11: 20–25
  41. Müller RU, Haas CS, Sayer JA. Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan. *Clin Kidney J* 2018; 11: 62–69
  42. Raimann JG, Riella MC, Levin NW. International Society of Nephrology's Oby25 initiative (zero preventable deaths from acute kidney injury by 2025): focus on diagnosis of acute kidney injury in low-income countries. *Clin Kidney J* 2018; 11: 12–19
  43. Ross DW, Abbasi MM, Jhaveri KD et al. Lung ultrasonography in end-stage renal disease: moving from evidence to practice—a narrative review. *Clin Kidney J* 2018; 11: 172–178
  44. Sgambat K, Clauss S, Moudgil A. Cardiovascular effects of metabolic syndrome after transplantation: convergence of obesity and transplant-related factors. *Clin Kidney J* 2018; 11: 136–146
  45. Selvaskandan H, Pawluczyk I, Barratt J. MicroRNAs: a new avenue to understand, investigate and treat immunoglobulin A nephropathy? *Clin Kidney J* 2018; 11: 29–37
  46. Rodríguez-Ortiz ME, Pontillo C, Rodríguez M et al. Novel urinary biomarkers for improved prediction of progressive eGFR loss in early chronic kidney disease stages and in high risk individuals without chronic kidney disease. *Sci Rep* 2018; 8: 15940
  47. Montinaro V, Giliberti M, Villani C et al. Citation classics: ranking of the top 100 most cited papers in nephrology. *Clin Kidney J* 2019; 12: 6–18
  48. Pham PC, Khaing K, Sievers TM et al. 2017 update on pain management in patients with chronic kidney disease. *Clin Kidney J* 2017; 10: 688–697
  49. Rak A, Raina R, Suh TT et al. Palliative care for patients with end-stage renal disease: approach to treatment that aims to improve quality of life and relieve suffering for patients (and families) with chronic illnesses. *Clin Kidney J* 2017; 10: 68–73
  50. Christiadi D, Singer RF. Calciphylaxis in a dialysis patient successfully treated with high-dose vitamin K supplementation. *Clin Kidney J* 2018; 11: 528–529
  51. Sparta G, Gaspert A, Neuhaus TJ et al. Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: change in treatment modality? A report of a case series. *Clin Kidney J* 2018; 11: 479–490
  52. Musso CG, Castañeda A, Giordani M et al. Hyponatremia in kidney transplant patients: its pathophysiologic mechanisms. *Clin Kidney J* 2018; 11: 581–585
  53. Wilkinson TJ, Watson EL, Gould DW et al. Twelve weeks of supervised exercise improves self-reported symptom burden and fatigue in chronic kidney disease: a secondary analysis of the 'ExTra CKD' trial. *Clin Kidney J* 2019; 12: 113–121
  54. Ruckle D, Keheila M, West B. Should donors who have used marijuana be considered candidates for living kidney donation? *Clin Kidney J* 2018; doi: 10.1093/ckj/sfy107
  55. Herrington WG, Preiss D, Haynes R et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. *Clin Kidney J* 2018; 11: 749–761
  56. Walsh PR, Tse Y, Ashton E et al. Clinical and diagnostic features of Bartter and Gitelman syndromes. *Clin Kidney J* 2018; 11: 302–309
  57. Lloyd IE, Gallan A, Huston HK et al. C3 glomerulopathy in adults: a distinct patient subset showing frequent association with monoclonal gammopathy and poor renal outcome. *Clin Kidney J* 2016; 9: 794–799
  58. Sprangers B, Nair V, Launay-Vacher V et al. Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network. *Clin Kidney J* 2018; 11: 315–329